Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Alnylam Authorizes Again

Last week, Alnylam (Nasdaq: ALNY  ) announced that it had licensed its patents covering the use of RNAi to Shanghai GenePharma of China. If previous such deals are any guide, investors shouldn't be too impressed.

These RNAi licenses have considerable profit potential, since they can be doled out to multiple companies. Alnylam has granted licenses to around 20 companies that are developing RNAi therapeutics or selling reagents to scientists performing RNAi research.

Unfortunately, these licenses aren't yet bringing in big bucks. Alnylam didn't disclose the financial details of its latest deal, but last year, licenses brought in just $1.4 million (down from the 2006 amount, because Alnylam signed up fewer companies). For a company with $144 million in operating expenses last year, the licenses clearly aren't doing much to lower its cash burn.

At some point, Alnylam's intellectual property might be worth as much as PDL BioPharma's (Nasdaq: PDLI  ) patent on humanized monoclonal antibodies -- $221 million and growing -- but some of those RNAi therapeutics will have to hit it big before royalty income becomes a sizable portion of Alnylam's revenue.

Until then, the company will have to rely on its partners Roche, Novartis (NYSE: NVS  ) , Biogen Idec (Nasdaq: BIIB  ) , and the U.S. government to fund about a third of its operating expenses, with the rest being funded from its own cash. Fortunately, like most drug companies, Alnylam has a lot of it. It ended last year with more than $455 million and expects to burn through only $65 million this year.

I've been critical of the valuation that investors have put on RNAi technology. While I still think investors are taking a lot of risk, at least Alnylam has plenty of time to get the kinks worked out, even if the funding won't be coming from patent-licensing deals.

More Foolishness:

Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 605222, ~/Articles/ArticleHandler.aspx, 10/26/2016 1:56:10 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 4 hours ago Sponsored by:
DOW 18,169.27 -53.76 -0.30%
S&P 500 2,143.16 -8.17 -0.38%
NASD 5,283.40 -26.43 -0.50%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/25/2016 4:00 PM
ALNY $36.67 Down -0.53 -1.42%
Alnylam Pharmaceut… CAPS Rating: ***
BIIB $286.00 Down -4.78 -1.64%
Biogen CAPS Rating: *****
NVS $72.63 Down -2.82 -3.74%
Novartis CAPS Rating: ****
PDLI $3.21 Up +0.04 +1.26%
PDL BioPharma CAPS Rating: ***